Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Archemix and Elan have joined forces to discover and develop aptamers, single-stranded nucleic acids whose binding behavior is similar to that of antibodies, for the treatment of autoimmune disease. Archemix snares a $7 million up-front payment from Elan and could receive more than $350 million in milestones and royalties. The companies will target IL-23, a cytokine that is a mediator in chronic autoimmune inflammatory diseases such as multiple sclerosis, Crohn's disease, psoriasis, and rheumatoid arthritis.
This article has been sent to the following recipient: